Bristol-Myers Squibb (BMS) is a major American pharmaceutical company headquartered in New York City. Following the 2019 acquisition of Celgene and the 2023 acquisition of Mirati Therapeutics, BMS has become a significant player in oncology and maintains active interests in neuroscience research.
- Headquarters: New York City, New York, USA
- Founded: 1887 (Bristol-Myers), 1897 (Squibb), merged 1989
- Ticker: BMY (NYSE)
- Market Cap: ~$130B (as of 2024)
- Employees: ~34,000
| Program |
Target/Mechanism |
Indication |
Phase |
Status |
| BMS-986446 |
Tau antibody |
Alzheimer's Disease |
Preclinical |
Research |
| BMS-986260 |
LRRK2 inhibitor |
Parkinson's Disease |
Discovery |
Research |
| BMS-986165 |
TYK2 inhibitor |
Alzheimer's (neuroinflammation) |
Phase 1 |
Active |
| Ozanimod |
S1P receptor modulator |
MS, IBD |
Approved |
Marketed |
| Prestimcelimab |
CD19 CAR-T |
Autoimmune |
Phase 2 |
Research |
BMS's neuroscience research leverages multiple platform technologies:
- Protein kinase expertise: Originally developed through oncology programs, now applied to neurodegeneration targets including LRRK2 and TYK2
- Cell therapy: Following Celgene acquisition, BMS gained access to CAR-T platforms with potential CNS applications
- Genomics and biomarkers: Precision medicine approaches for patient stratification in neurodegeneration trials
- Small molecule inhibitors: Broad kinase inhibitor library for CNS targets including tau and alpha-synuclein
BMS maintains several Alzheimer's disease programs targeting different pathological mechanisms:
- Tau antibody (BMS-986446): Preclinical anti-tau therapeutic targeting neurofibrillary tangles, a key pathological hallmark of AD
- TYK2 inhibition (BMS-986165): Neuroinflammation modulation through JAK/STAT pathway inhibition, addressing microglial activation in AD
- Novel mechanisms: Synaptic plasticity and cognitive enhancement programs in early development
BMS has a growing Parkinson's disease portfolio:
- LRRK2 inhibitor (BMS-986260): Targeting LRRK2 kinase, the most common genetic cause of familial PD (affecting ~5-10% of cases)
- Alpha-synuclein targeting: Aggregation inhibition approaches for the hallmark protein of PD
BMS previously developed cinpanemab (BIIB054), an anti-alpha-synuclein monoclonal antibody, through its neurodegeneration research:
- Mechanism: mAb targeting alpha-synuclein fibrils
- Target: Pathological alpha-synuclein species
- Phase: Phase 2 (SPARK study)
- Status: Development discontinued after Phase 2 did not meet primary endpoint
- Note: Program provided valuable insights into alpha-synuclein immunotherapy
The company continues to explore alpha-synuclein targeting approaches through internal research and external partnerships.
- Neuroprotective strategies: Mitochondrial function and autophagy modulation programs
- Multiple Sclerosis: Ozanimod, an S1P receptor modulator, is approved for MS and IBD
- Autoimmune encephalitis: CAR-T cell therapy approaches in development
BMS has been expanding its neuroscience clinical trials portfolio:
- Neuroinflammation trials: TYK2 inhibitors being evaluated in AD patients for anti-inflammatory effects
- Partnered programs: External collaborations with academia and biotech for additional CNS assets
- Biomarker development: tau PET imaging and CSF biomarker programs for patient selection and response monitoring
BMS maintains an active partnership strategy in neuroscience:
- Academic collaborations: Partnerships with leading US universities including MIT, Harvard, and Stanford
- Consortium involvement: Participation in various neurodegeneration research initiatives and public-private partnerships
- External innovation: BMS New York incubator programs for early-stage neuroscience ventures
Strategic acquisitions have shaped BMS's current position:
- 2019: Acquired Celgene for $74 billion — gained CAR-T and inflammatory disease platforms
- 2023: Acquired Mirati Therapeutics for $5.8 billion — expanded oncology pipeline
- Multiple academic and biotech partnerships in neuroscience
- Market Cap: ~$130 billion USD (2024)
- R&D Budget: ~$12 billion annually
- Neuroscience allocation: Estimated 3-5% of R&D budget
- Revenue (2024): ~$45 billion